CLDX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
["Not a good buy right now for an impatient investor: there are no proprietary buy signals, momentum is still weak (MACD < 0), and near-term pattern stats skew negative (next week/month bias).", "Price is sitting just below the pivot (25.491) with nearby support at 24.341\u2014risk/reward is not attractive if you need immediate upside follow-through.", "Wall Street\u2019s latest stance (Barclays Equal Weight/previous Underweight) and price target ($24) sit below the current price (~25.29), limiting upside narrative today."]
["Trend/Momentum: MACD histogram at -0.13 (below zero) = bearish momentum, though contracting suggests downside pressure may be slowing rather than reversing.", "RSI (6) ~45.55 = neutral-to-soft; not oversold, so no strong mean-reversion buy signal.", "Moving averages: converging = consolidation/indecision, not a clean uptrend.", "Key levels: Current ~25.285 is slightly below Pivot 25.491 (mildly bearish). Support: S1 24.341 then S2 23.631. Resistance: R1 26.641 then R2 27.351.", "Pattern-based forward view (similar candlesticks): ~-2.45% next week and ~-6.94% next month bias\u2014doesn\u2019t support an immediate buy.", "Intellectia Proprietary Trading Signals\n- AI Stock Picker: no signal on given stock today.\n- SwingMax: No signal on given stock recently."]
["Losses improved YoY in 2025/Q3 (net loss and EPS loss narrowed materially), which can support the stock if the market re-prices progress expectations.", "No heavy recent insider or hedge-fund trend signal (both neutral), reducing the risk of a clear informed-selling overhang from those groups (based on provided data)."]
is below the current price (~$25.29).", "Fundamentals still show no revenue in the latest quarter (2025/Q3), reinforcing pre-commercial risk/uncertainty."]
["Latest quarter: 2025/Q3.", "Revenue: dropped to 0 (down -100% YoY), indicating no meaningful operating revenue base in the period.", "Profitability: Net income improved to -$67.044M (59.17% YoY improvement), and EPS improved to -1.01 (57.81% YoY improvement) \u2014 losses are narrowing but still significant.", "Gross margin: listed at 100 (flat YoY), consistent with minimal/irregular revenue dynamics rather than scaling commercial operations."]
["Recent trend: Barclays lowered PT to $21 (from $25) and kept Underweight after Q3 (2025-11-11), then later raised PT to $24 (from $21) while keeping a cautious Equal Weight rating (2025-12-17).", "Net takeaway: sentiment improved modestly versus the immediate post-earnings cut, but the latest PT ($24) remains below the current price (~$25.29) \u2014 pros see limited near-term upside.", "Wall Street pros/cons (from provided data):\n- Pros: modest PT rebound into 2026 outlook suggests less bearishness than before.\n- Cons: prior Underweight and still-not-bullish stance (Equal Weight) + PT below market price argues against buying aggressively today."]
